News
Latest valve and structural heart intelligence
Filter by Source
All SourcesAHA Heart NewsCardiovascular BusinessCirculationDiagnostic & Interventional CardiologyHealio Cardiology
Filter by Tag
ACCAHAAbbottAnticoagulationBoston ScientificCMSCongenitalDurabilityESCEdwardsFDAGuidelinesHigh RiskImagingLeafletLow RiskMarketMedtronicMinimally InvasiveRedo-TAVR
Clear filters1 articles tagged Boston Scientific
CVB
industry·about 2 months ago·Cardiovascular Business
Boston Scientific invests $1.5B in MiRus with option to buy its TAVR business
Boston Scientific invested $1.5 billion in MiRus with an option to acquire its transcatheter aortic valve replacement (TAVR) business. The strategic investment provides Boston Scientific access to MiRus's TAVR platform and optionality in the structural heart valve market.
Digest: This major investment signals Boston Scientific's intent to enter or expand in the TAVR market, potentially reshaping competitive dynamics currently dominated by Edwards and Medtronic.